Sodium channel protein type 10 subunit alpha · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Sodium channel protein type 10 subunit alpha shows clinical signal disease relevance led by overactive bladder. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y5Y9. Start with overactive bladder, then reuse UniProt Q9Y5Y9 as the stable protein anchor across project notes and exports.
Start with overactive bladder, then reuse UniProt Q9Y5Y9 as the stable protein anchor across project notes and exports.
Sodium channel protein type 10 subunit alpha shows clinical signal disease relevance led by overactive bladder. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with overactive bladder because it currently carries clinical signal support. Linked drugs include AFACIFENACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySodium channel protein type 10 subunit alpha
Review this target as Sodium channel protein type 10 subunit alpha, mapped to UniProt Q9Y5Y9. Sequence length is 1956 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel protein type 10 subunit alpha as ChEMBL target CHEMBL5451, mapped to UniProt Q9Y5Y9. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sodium channel protein type 10 subunit alpha is the right protein anchor across sources, using UniProt Q9Y5Y9 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why overactive bladder is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sodium channel protein type 10 subunit alpha |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9Y5Y9 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Sodium channel protein type 10 subunit alpha |
| UniProt Accession | Q9Y5Y9 |
| Component Type | Protein |
| Sequence Length | 1956 aa |
Sodium channel protein type 10 subunit alpha
Review this target as Sodium channel protein type 10 subunit alpha, mapped to UniProt Q9Y5Y9. Sequence length is 1956 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Sodium channel protein type 10 subunit alpha shows clinical signal disease relevance led by overactive bladder. 2 more disease programs remain visible in the same review block.
Start review with overactive bladder because it currently carries clinical signal support. Linked drugs include AFACIFENACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4760292 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL4798938 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL4777598 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL4753280 | 9.1 | IC50 | 0.8 | Preclinical |
| CHEMBL5845128 | 9.1 | IC50 | 0.8 | Preclinical |
| CHEMBL4781110 | 9.05 | IC50 | 0.9 | Preclinical |
| CHEMBL1277958 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3678273 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4745699 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4744908 | 8.89 | IC50 | 1.3 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 76 | 235 | 6.6 |
| single protein format | 14 | 251 | 7.2 |
| assay format | 13 | 273 | 6.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 4 | 0 | — |